Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark C Markowski

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Biorxiv : the Preprint Server for Biology|March 3, 2023
MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progressionJiayu Chen, Qizhi Zheng, Jessica L Hicks, et al.
JAMA Oncology|August 22, 2024
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled TrialCatherine H Marshall, Benjamin A Teply, Jiayun Lu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2021
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or EnzalutamideKatherine A Zukotynski, Urban Emmenegger, Sebastien Hotte, et al.
The Prostate|January 12, 2023
Lack of repeatability of radiomic features derived from PET scans: Results from a <sup>18</sup> F-DCFPyL test-retest cohortRudolf A Werner, Bilêl Habacha, Susanne Lütje, et al.
Nature Communications|January 3, 2024
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trialMark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, et al.
Molecular Imaging|March 14, 2022
High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with <sup>18</sup>F-DCFPyLRudolf A Werner, Bilêl Habacha, Susanne Lütje, et al.
Cancer Research|October 14, 2021
Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate CancerRajendra Kumar, Janet Mendonca, Olutosin Owoyemi, et al.
Cancer Research Communications|July 30, 2024
High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II TrialChanning J Paller, Marianna L Zahurak, Adel Mandl, et al.
The Journal of Clinical Investigation|October 4, 2022
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYCLaura A Sena, Rajendra Kumar, David E Sanin, et al.
JNCI Cancer Spectrum|April 25, 2020
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid TumorsSarina A Piha-Paul, Christine L Hann, Christopher A French, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Biorxiv : the Preprint Server for Biology|March 3, 2023
MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progressionJiayu Chen, Qizhi Zheng, Jessica L Hicks, et al.
JAMA Oncology|August 22, 2024
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled TrialCatherine H Marshall, Benjamin A Teply, Jiayun Lu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2021
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or EnzalutamideKatherine A Zukotynski, Urban Emmenegger, Sebastien Hotte, et al.
The Prostate|January 12, 2023
Lack of repeatability of radiomic features derived from PET scans: Results from a <sup>18</sup> F-DCFPyL test-retest cohortRudolf A Werner, Bilêl Habacha, Susanne Lütje, et al.
Nature Communications|January 3, 2024
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trialMark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, et al.
Molecular Imaging|March 14, 2022
High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with <sup>18</sup>F-DCFPyLRudolf A Werner, Bilêl Habacha, Susanne Lütje, et al.
Cancer Research|October 14, 2021
Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate CancerRajendra Kumar, Janet Mendonca, Olutosin Owoyemi, et al.
Cancer Research Communications|July 30, 2024
High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II TrialChanning J Paller, Marianna L Zahurak, Adel Mandl, et al.
The Journal of Clinical Investigation|October 4, 2022
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYCLaura A Sena, Rajendra Kumar, David E Sanin, et al.
JNCI Cancer Spectrum|April 25, 2020
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid TumorsSarina A Piha-Paul, Christine L Hann, Christopher A French, et al.
Pageof 8